Explore the words cloud of the ADAPTED project. It provides you a very rough idea of what is the project "ADAPTED" about.
The following table provides information about the project.
|Coordinator Country||Spain [ES]|
|Total cost||6˙796˙740 €|
|EC max contribution||3˙510˙000 € (52%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2016-10-01 to 2020-03-31|
Take a look of project's partnership.
|1||FUNDACIO ACE||ES (BARCELONA)||coordinator||333˙757.00|
|2||AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS||ES (MADRID)||participant||688˙476.00|
|3||UNIVERSITEIT LEIDEN||NL (LEIDEN)||participant||470˙677.00|
|4||UNIVERSITATSKLINIKUM BONN||DE (BONN)||participant||429˙850.00|
|5||ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM||NL (ROTTERDAM)||participant||420˙500.00|
|6||MIMETAS BV||NL (Leiden)||participant||305˙102.00|
|7||CAEBI BIOINFORMATICA SOCIEDAD LIMITADA||ES (SEVILLA)||participant||282˙062.00|
|8||KLINIKUM DER UNIVERSITAET ZU KOELN||DE (KOELN)||participant||244˙812.00|
|9||DC BIOSCEINCES LTD||UK (DUNDEE)||participant||186˙514.00|
|10||MODUS RESEARCH AND INNOVATION LIMITED||UK (EDINBURGH)||participant||110˙337.00|
|11||KITE INNOVATION (EUROPE) LIMITED||UK (HUDDERSFIELD)||participant||37˙912.00|
|12||ABBVIE DEUTSCHLAND GMBH & CO KG||DE (WIESBADEN)||participant||0.00|
|13||BIOGEN IDEC LIMITED||UK (MAIDENHEAD)||participant||0.00|
|14||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
APOEÉ›4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect both the vasculature and the brain. This complexity and pleiotropic influence demands an integrated hypothesis-free approach to embark on a fundamental study of the gene, the phenotype and modulation by other risk factors. ADAPTED proposes to leverage extreme genotypes from consortium cohorts dating back more than 25 years to generate, and use existing, lines of human induced pluripotent stem cells (iPSC). These cells, with blood cells, will form the backbone of the research programme. We will differentiate them to the most relevant cells for APOE and AD studies and with gene editing create bespoke homozygote É›3 and É›2 cells for a highly focussed effort on APOE biology. A series of experiments including neuron-astrocyte and macrophage-endothelium co-culture and Organ on a Chip models combined with state-of-the-art omics including quantitative proteomics assays will generate data for rigorous integrated analysis to uncover new signalling pathways related to APOE. Lipid homeostasis, endocytosis, metabolism and immune systems pathways will be investigated in a broad approach. The findings are expected to lead to identification of new treatment approaches and blood based AD signatures with a temporal dimension from the earliest stages of risk identification and progression through MCI to AD. Testing and validation of biomarkers will be performed by examining their influence and predictive capacity in a longitudinal ADAPTED cohort harmonised using a combination of approaches for marker and diagnostic consistency. The impact of this work can be expected to include seminal new finding to illuminate the research path towards new diagnostics and therapies to attenuate the rising tide of suffering from AD. The vision is a follow on with clinical proof of concept validating utility of the results within two years of the end of ADAPTED.
|Definition of cognitive composite scores to evaluate rate of disease progression based on cognitive function decline in the ADAPTED cohorts||Websites, patent fillings, videos etc.||2020-04-08 21:10:07|
Take a look to the deliverables list in detail: detailed list of ADAPTED deliverables.
|year||authors and title||journal||last update|
Michael Peitz, Tamara Bechler, Catrin Cornelia Thiele, Monika Veltel, Melanie Bloschies, Klaus Fliessbach, Alfredo Ramirez, Oliver BrÃ¼stle
Blood-derived integration-free iPS cell line UKBi011-A from a diagnosed male Alzheimer\'s disease patient with APOE É›4/É›4 genotype
published pages: 250-253, ISSN: 1873-5061, DOI: 10.1016/j.scr.2018.04.011
|Stem Cell Research 29||2020-04-08|
Sven J. van der Lee, Charlotte E. Teunissen, RenÃ© Pool, Martin J. Shipley, Alexander Teumer, Vincent Chouraki, Debora Melo van Lent, Juho Tynkkynen, Krista Fischer, Jussi Hernesniemi, Toomas Haller, Archana Singh-Manoux, Aswin Verhoeven, Gonneke Willemsen, Francisca A. de Leeuw, Holger Wagner, Jenny van Dongen, Johannes Hertel, Kathrin Budde, Ko Willems van Dijk, Leonie Weinhold, M. Arfan Ikram, Maik Pietzner, Markus Perola, Michael Wagner, Nele Friedrich, P. Eline Slagboom, Philip Scheltens, Qiong Yang, Robert E. Gertzen, Sarah Egert, Shuo Li, Thomas Hankemeier, Catharina E.M. van Beijsterveldt, Ramachandran S. Vasan, Wolfgang Maier, Carel F.W. Peeters, Hans JÃ¶rgen Grabe, Alfredo Ramirez, Sudha Seshadri, Andres Metspalu, Mika KivimÃ¤ki, Veikko Salomaa, AyÅŸe Demirkan, Dorret I. Boomsma, Wiesje M. van der Flier, Najaf Amin, Cornelia M. van Duijn
Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies
published pages: , ISSN: 1552-5260, DOI: 10.1016/j.jalz.2017.11.012
|Alzheimer\'s & Dementia||2020-04-08|
Nienke R. Wevers, Dhanesh G. Kasi, Taylor Gray, Karlijn J. Wilschut, Benjamin Smith, Remko van Vught, Fumitaka Shimizu, Yasuteru Sano, Takashi Kanda, Graham Marsh, Sebastiaan J. Trietsch, Paul Vulto, HenriÃ«tte L. Lanz, Birgit Obermeier
A perfused human bloodâ€“brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport
published pages: , ISSN: 2045-8118, DOI: 10.1186/s12987-018-0108-3
|Fluids and Barriers of the CNS 15/1||2020-04-08|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADAPTED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ADAPTED" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More